Umbralisib, a PI3K/CK1 Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL TrialNilanjan Ghosh,Pier Luigi Zinzani,Felipe Samaniego,Wojciech Jurczak,Enrico Derenzini,James A. Reeves,Wanda Knopinska-Posluszny,Chan Y. Cheah,Tycel Phillips,Ewa Lech-Maranda,Bruce Cheson,Paolo Caimi,Sebastian Grosicki,Lori A. Leslie,Julio C. Chavez,Gustavo Fonseca,Sunil Babu,Daniel J. Hodson,Spencer H. Shao,John M. Burke,Jeff P. Sharman,Jennie Y. Law,John M. Pagel,Hari P. Miskin,Peter Sportelli,Owen A. O'Connor,Michael S. Weiss,Nathan H. FowlerCLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2021）引用 0|浏览20暂无评分关键词PI3K,marginal zone lymphoma,follicular lymphoma,small lymphocytic lymphoma,targetedAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
